Navigation Links
Oncolytics Biotech(R) Inc. Announces Unit Offering
Date:11/17/2009

ks and uncertainties include, among others, the pricing and completion of the contemplated offering, availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
3. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
8. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
9. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
10. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
11. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... WESTWOOD, Mass. , Aug. 3, 2015  Merck ... company for innovative and top-quality high-tech products in the ... together with the US-based company Nano-C, their development and ... field of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... participate in the growing OPV sector. Novel ...
(Date:8/3/2015)... , Aug. 3, 2015   Intrexon Corporation ... first half and second quarter 2015 financial results after ... 2015.  The Company will host a conference call at ... a general business update. The conference call ... 1-412-902-4262 (International), and asking to join the "Intrexon Corporation ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/30/2015)... ... 2015 , ... Ralco is honored to announce that it is the primary ... held August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where ... impacts their daily lives. This unique exhibit also features a birthing center for fair ...
Breaking Biology Technology:Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... Focusing On Diagnostic Products and Target Validation, ... Inc. announced today,that SomaLogic and Otsuka Pharmaceutical ... use SomaLogic,s proprietary aptamer technology,to discover and ... research,tools that will enhance Otsuka,s pharmaceutical discovery ...
... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today announced ... approval from the U.S. Food and Drug,Administration (FDA) ... and market a generic version of Yasmin(R) (drospirenone ... marketed,by Bayer Schering Pharma, AG., On March ...
... Planting Season, BEIJING and CLAREMONT, Calif., May ... Bulletin Board: KWBT),announced revenues for the first quarter ... of 57.8% above revenues of $1,384,093 for the ... is due to the expansion in Kiwa,s,bio-fertilizer and ...
Cached Biology Technology:SomaLogic and Otsuka Enter Into Research Collaboration 2SomaLogic and Otsuka Enter Into Research Collaboration 3Barr Announces Approval of Generic Yasmin(R) 2Barr Announces Approval of Generic Yasmin(R) 3Kiwa Bio-Tech 1st Quarter Revenues Increase 57.8% - $2.18 Million 2Kiwa Bio-Tech 1st Quarter Revenues Increase 57.8% - $2.18 Million 3
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... University of Illinois weed scientist Patrick Tranel got more genetic ... lab. The genetic information was obtained using pyrosequencing technology in ... sequence will allow scientists to study herbicide resistance in waterhemp. ... refers to as "important species" such as humans, cows, fruit ...
... 5 August 2009 - It is important to understand ... be resilient under conditions of extreme stress, such as ... Dr. Charles A. Morgan III and his colleagues from ... have worked closely with collaborators at the Special Forces ...
... U.S Department of Energy Secretary Steven Chu announced ... from the American Recovery and Reinvestment Act will go ... of DOE,s national laboratories in six states will be ... learning across the nation. "These new initiatives ...
Cached Biology News:Understanding how weeds are resistant to herbicides 2Understanding how weeds are resistant to herbicides 3Understanding how weeds are resistant to herbicides 4Hormone levels contribute to stress resilience 2Obama administration announces more than $327 million in Recovery Act funding for science research 2Obama administration announces more than $327 million in Recovery Act funding for science research 3
Recognizes Human Connexin 45. Due to sequence homologies, this antibody is also expected to react with canine (100% homology) and mouse (92% homology) Connexin 45. Also confirmed to work on rat C6 c...
... a hydrophobic barrier pen for immunohistochemistry and ... with frozen or paraffin-embedded tissue sections mounted ... a heat-stable, water-repellent barrier that keeps staining ... mixing of reagents when differentially staining two ...
...
...
Biology Products: